about
Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini ReviewThe complex interplay between cyclooxygenase-2 and angiotensin II in regulating kidney functionAssociation of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis.Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis.Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.Cardiovascular risk and COX-2 inhibition in rheumatological practice.Morphine promotes renal pathology in sickle mice.Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugsEvaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxibProstaglandin E2 induces chloride secretion through crosstalk between cAMP and calcium signaling in mouse inner medullary collecting duct cells.Hyperkalemia in patients with heart failure: incidence, prevalence, and management.Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low sodium diet.3rd Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology.Impaired responsiveness of renal mechanosensory nerves in heart failure: role of endogenous angiotensin.Nimesulide, a cyclooxygenase-2 preferential inhibitor, impairs renal function in the newborn rabbit.Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria.ISFM and AAFP consensus guidelines: long-term use of NSAIDs in cats.Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.Tacrolimus and nonsteroidal anti-inflammatory drugs: an association to be avoided.Vasopressin lowers renal epoxyeicosatrienoic acid levels by activating soluble epoxide hydrolase.
P2860
Q24634894-53070613-24E2-478E-B8F7-E770589645FEQ26995081-EE5794B3-1842-4A32-BC02-9B0A4F49277CQ34571335-9D96875D-795A-405B-B5B8-E9120488952FQ35102135-8877BDD9-AE55-4ED5-BAA0-720FCA3DA043Q35195182-A85269FF-139E-4EDC-B72D-DD9B32E49BC8Q35896154-650843E8-89F7-496E-AA28-393484641996Q36144403-16FAB2D4-37DF-4214-AD66-6243CCF0B7CAQ36349740-31898785-1700-4C77-8CB6-77290AB2D00AQ36622844-0E5591E8-989D-48E8-AB20-6777380F2298Q37175779-60F0AB83-EF31-4F69-901E-1545AC951460Q37575373-6F9B76C7-4C48-44AA-A621-D0A88F1EB7D8Q37641425-9B78B825-3ADF-47F8-99B0-87E7C8292CC0Q41833844-6430ED17-9C6E-43E8-9659-B27C56329FCEQ42134079-02D470F5-E97A-4F38-837E-64901B42133DQ44185871-BB47321F-6E1C-4BB4-9FB4-7456EDC3BAB8Q44647112-7C31E2E1-5887-4DFC-A64E-813A320B47B8Q45038781-AC5BB4AD-3015-4A1B-85AB-67F35F030BF1Q45968059-61F707FE-FCF7-4F9A-AC69-4B4D31278621Q46043878-B7F56616-4036-49CD-B638-A7A89C4C3F3AQ46565086-BD991E1F-4C23-4DFE-93E7-7DF096D9DAEBQ51452426-06E9F2A7-C971-4428-A39F-FD8B129AB4E0
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cyclooxygenase-2 inhibition and renal physiology.
@ast
Cyclooxygenase-2 inhibition and renal physiology.
@en
Cyclooxygenase-2 inhibition and renal physiology.
@nl
type
label
Cyclooxygenase-2 inhibition and renal physiology.
@ast
Cyclooxygenase-2 inhibition and renal physiology.
@en
Cyclooxygenase-2 inhibition and renal physiology.
@nl
prefLabel
Cyclooxygenase-2 inhibition and renal physiology.
@ast
Cyclooxygenase-2 inhibition and renal physiology.
@en
Cyclooxygenase-2 inhibition and renal physiology.
@nl
P1476
Cyclooxygenase-2 inhibition and renal physiology.
@en
P2093
Raymond C Harris
P304
P356
10.1016/S0002-9149(02)02232-4
P407
P577
2002-03-01T00:00:00Z